Request Free Sample ×
ReportInfographic

Kindly complete the form below to receive a free sample of this Report

* Please use a valid business email

Leading companies partner with us for data-driven Insights

clients tt-cursor

Vasomotor Symptoms Companies

ID: MRFR/HC/8332-HCR
153 Pages
Rahul Gotadki
Last Updated: February 16, 2025
Addressing women's health, Vasomotor Symptoms companies focus on solutions for menopausal symptoms. Through research and innovation, they offer therapies to alleviate vasomotor symptoms like hot flashes and night sweats, enhancing the quality of life for women transitioning through menopause.
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Vasomotor Symptoms Market
Market Size
Forecast Period2025 - 2035
CAGR (2025 - 2035)7.77%
2024 Market Size$ 4.02 Billion
2025 Market Size$ 4.33 Billion
2035 Market Size$ 9.16 Billion
Key Players
Pfizer
Bristol-Myers Squibb
AbbVie
Mylan
Teva Pharmaceuticals
Hoffmann-La Roche
Trends
  • Rising Awareness and Education
  • Technological Advancements in Treatment
  • Patient-Centric Approaches
Opportunities
  • Growing Focus on Personalized Medicine
  • Advancements in Hormone Replacement Therapy
  • Increasing Prevalence of Vasomotor Symptoms
Summary Table of Contents Segmentation Methodology Download PDF

Top Industry Leaders in the Vasomotor Symptoms Market

Vasomotor Symptoms Key Companies
 
Latest Vasomotor Symptoms Companies Update:

Astellas' VEOZATM Received EU approval in December 2023 and US FDA approval in May 2023 for treating moderate to severe VMS due to menopause.First non-hormonal neurokinin 3 (NK3) receptor antagonist approved for VMS, offering a new option for women seeking non-hormonal treatment.

Abbott's Upledity Launched in the US in November 2023 for moderate to severe VMS and other menopausal symptoms. Offers a new low-dose oral hormonal option for some women.

Therapeutics Unlimited's Zyla Received FDA approval in November 2023 for the treatment of menopausal symptoms, including VMS. Offers a new topical estrogen option for women seeking to avoid systemic treatments.

List of Vasomotor Symptoms Key companies in the market
  • Allergan (Ireland)
  • Pfizer Inc. (US)
  • Eli Lily and Company (US)
  • Novartis AG (Switzerland)
  • Emcure Pharmaceuticals Ltd (India)
  • Merck & Co.Inc. (US)
  • TherapeuticsMD Inc. (US)
  • Mithra Pharmaceuticals (Belgium)

Related Reports

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035